Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
October 2025
Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: A substudy of the SENSCIS trial
RMD Open 2025;11:e005704 Doi:10.1136/rmdopen-2025-005704
In a substudy of the SENSCIS trial, Smith et al. showed that numerical differences in changes in capillary density assessed by nailfold capillaroscopy (NC) over 52 weeks may suggest a potential effect of nintedanib in patients at risk of ILD progression. Authors assessed microvascular changes in nailfold capillaries in patients with SSc-ILD who received nintedanib or PBO in a sub-study of the SENSCIS trial.